| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 John T. Mather Memorial Hospital, Port Jefferson, NY 11777.
2 Hartford Hospital, Hartford, CT 06102.
3 Hennepin County Medical Center, Minneapolis, MN 55415.
4 Jewish Hospital, Louisville, KY 40202.
5 University of Uppsala, S-751-85 Uppsala, Sweden.
6 Beckman Coulter, Inc., Fullerton, CA 92835.
aAddress correspondence to this author at: Immunoassay Development, Beckman Coulter, Inc., 1000 Lake Hazeltine Dr., Chaska, MN 55318. Fax 952-368-1620; e-mail schan{at}beckman.com.
Background: Cardiac troponin I (cTnI) is a powerful tool to aid in the diagnosis of myocardial infarction and cardiac muscle damage. We describe an assay that overcomes problems of early assays that were often affected by cTnI degradation, assay interference, poor sensitivity, and imprecision.
Methods: The analytical performance of the Access® AccuTnITM assay (Beckman Coulter) was evaluated at five institutions. Controls, zero calibrator, and diluted patient samples were used to determine precision, detection limit, functional sensitivity, and linearity. The 97.5 and 99 percentiles of a reference population were determined. Common interferents and heterophilic patient samples were tested. Equimolarity was determined by assaying samples with various ratios of free and complexed cTnI. Matched samples drawn into serum, EDTA, lithium heparin, and sodium heparin sample tubes were compared.
Results: Total imprecision (CVs) was 4.0–8.8% between 0.40 and 31 µg/L cTnI. The detection limit was <0.01 µg/L. The 97.5 percentile upper reference limit (URL) was 0.03 µg/L (CV = 20%), and the 99 percentile URL was 0.04 µg/L (CV = 14%). Total CVs of 10% and 20% were seen at and above 0.06 and 0.03 µg/L, respectively. The assay was linear to >60 µg/L and not affected by common assay interferents. An equimolar response was observed with free, complexed, phosphorylated, and dephosphorylated forms of cTnI. Results were 4% lower in serum and 14% lower in EDTA plasma than in lithium heparin plasma (P <0.01), independent of cTnI concentration.
Conclusion: AccuTnI is a sensitive and precise assay for the measurement of cTnI.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  N. Kilcullen, K. Viswanathan, R. Das, C. Morrell, A. Farrin, J. H. Barth, A. S. Hall, and for the EMMACE-2 Investigators Heart-Type Fatty Acid-Binding Protein Predicts Long-Term Mortality After Acute Coronary Syndrome and Identifies High-Risk Patients Across the Range of Troponin Values J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2061 - 2067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Eggers, B. Lagerqvist, P. Venge, L. Wallentin, and B. Lindahl Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality Circulation, October 23, 2007; 116(17): 1907 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vancraeynest, J. Kefer, C. Hanet, C. Fillee, C. Beauloye, A. Pasquet, B. L. Gerber, M. Philippe, and J.-L. J. Vanoverschelde Release of cardiac bio-markers during high mechanical index contrast-enhanced echocardiography in humans Eur. Heart J., May 2, 2007; 28(10): 1236 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Patti, V. Pasceri, G. Colonna, M. Miglionico, D. Fischetti, G. Sardella, A. Montinaro, and G. Di Sciascio Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention: Results of the ARMYDA-ACS Randomized Trial J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1272 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Patti, M. Chello, V. Pasceri, D. Colonna, A. Nusca, M. Miglionico, A. D'Ambrosio, E. Covino, and G. Di Sciascio Protection From Procedural Myocardial Injury by Atorvastatin Is Associated With Lower Levels of Adhesion Molecules After Percutaneous Coronary Intervention: Results From the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) Substudy J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1560 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. James, M. Flodin, N. Johnston, B. Lindahl, and P. Venge The Antibody Configurations of Cardiac Troponin I Assays May Determine Their Clinical Performance Clin. Chem., May 1, 2006; 52(5): 832 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zethelius, N. Johnston, and P. Venge Troponin I as a Predictor of Coronary Heart Disease and Mortality in 70-Year-Old Men: A Community-Based Cohort Study Circulation, February 28, 2006; 113(8): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Lam, M. Black, O. Youdell, H. Spilsbury, and H.-G. Schneider Performance Evaluation and Subsequent Clinical Experience with the Abbott Automated Architect STAT Troponin-I Assay Clin. Chem., February 1, 2006; 52(2): 298 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-S. Wang, C.-F. Feng, T.-K. Er, L.-Y. Tsai, C.-Y. Chen, S.-J. Chang, and B.-H. Chen Comparison of Cardiac Troponin I Levels in Serum and Sodium-Citrate Plasma Using the ACCESS 2 Immunoassay Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 453 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Panteghini Selection of Antibodies and Epitopes for Cardiac Troponin Immunoassays: Should We Revise Our Evidence-Based Beliefs? Clin. Chem., May 1, 2005; 51(5): 803 - 804. [Full Text] [PDF]
|
|
|
|
|
|
S. Eriksson, T. Ilva, C. Becker, J. Lund, P. Porela, K. Pulkki, L.-M. Voipio-Pulkki, and K. Pettersson Comparison of Cardiac Troponin I Immunoassays Variably Affected by Circulating Autoantibodies Clin. Chem., May 1, 2005; 51(5): 848 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Patti, G. Colonna, V. Pasceri, L. L. Pepe, A. Montinaro, and G. Di Sciascio Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Circulation, April 26, 2005; 111(16): 2099 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Boulier, I. Jaussent, N. Terrier, F. Maurice, J.-P. Rivory, L. Chalabi, A.-M. Boularan, C. Delcourt, A.-M. Dupuy, B. Canaud, et al. Measurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2313 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, G. Di Sciascio, and on behalf of the ARMYDA Investigators Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study Circulation, August 10, 2004; 110(6): 674 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pagani, F. Stefini, and M. Panteghini Innotrac Aio! Second-Generation Cardiac Troponin I Assay: Imprecision Profile and Other Key Characteristics for Clinical Use Clin. Chem., July 1, 2004; 50(7): 1271 - 1272. [Full Text] [PDF]
|
|
|
|
 |
|
 K A A Fox, J Birkhead, R Wilcox, C Knight, and J Barth British Cardiac Society Working Group on the definition of myocardial infarction Heart, June 1, 2004; 90(6): 603 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Panteghini The Interfering Component in Cardiac Troponin I Immunoassays: Need for Further Experimental Evidence Clin. Chem., March 1, 2004; 50(3): 676 - 677. [Full Text] [PDF]
|
|
|
|
|
|
M. Panteghini, F. Pagani, K.-T. J. Yeo, F. S. Apple, R. H. Christenson, F. Dati, J. Mair, J. Ravkilde, and A. H.B. Wu Evaluation of Imprecision for Cardiac Troponin Assays at Low-Range Concentrations Clin. Chem., February 1, 2004; 50(2): 327 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Wallace, E. Hausner, E. Herman, G. D. Holt, J. T. Macgregor, A. L. Metz, E. Murphy, I.Y. Rosenblum, F. D. Sistare, and M. J. York Serum Troponins as Biomarkers of Drug-Induced Cardiac Toxicity Toxicol Pathol, January 1, 2004; 32(1): 106 - 121. [PDF]
|
|
|
|
|
|
F. S. Apple, H. E. Quist, P. J. Doyle, A. P. Otto, and M. M. Murakami Plasma 99th Percentile Reference Limits for Cardiac Troponin and Creatine Kinase MB Mass for Use with European Society of Cardiology/American College of Cardiology Consensus Recommendations Clin. Chem., August 1, 2003; 49(8): 1331 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow, N. Rifai, M. S. Sabatine, S. Ayanian, S. A. Murphy, J. A. de Lemos, E. Braunwald, and C. P. Cannon Evaluation of the AccuTnI Cardiac Troponin I Assay for Risk Assessment in Acute Coronary Syndromes Clin. Chem., August 1, 2003; 49(8): 1396 - 1398. [Full Text] [PDF]
|
|
|
|
|
|
P. Venge, N. Johnston, B. Lagerqvist, L. Wallentin, and B. Lindahl Clinical and Analytical Performance of the Liaison Cardiac Troponin I Assay in Unstable Coronary Artery Disease, and the Impact of Age on the Definition of Reference Limits. A FRISC-II Substudy Clin. Chem., June 1, 2003; 49(6): 880 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Herrmann, J. Scharhag, M. Miclea, A. Urhausen, W. Herrmann, and W. Kindermann Post-Race Kinetics of Cardiac Troponin T and I and N-Terminal Pro-Brain Natriuretic Peptide in Marathon Runners Clin. Chem., May 1, 2003; 49(5): 831 - 834. [Full Text] [PDF]
|
|
|
|
|
|
M. Panteghini Performance of Today's Cardiac Troponin Assays and Tomorrow's Clin. Chem., June 1, 2002; 48(6): 809 - 810. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
